BiotechTube
Profound Medical

Profound Medical

PROF
Mississauga, Canada· Est.
profoundmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

PROF · Stock Price

USD 7.16+2.88 (+67.29%)
Market Cap: $275.8M

Historical price data

Overview

Profound Medical's mission is to transform patient care through precise, predictable, and radiation-free ablation therapies. Its key achievement is the FDA-cleared and CE-marked TULSA-PRO® system, which recently demonstrated superior functional preservation versus robotic prostatectomy in the pivotal CAPTAIN randomized controlled trial. The company's strategy involves direct commercialization and strategic partnerships to penetrate the global prostate disease market while exploring new indications for its Sonalleve® platform in oncology.

OncologyUrologyWomen's Health

Technology Platform

Integrated platform combining real-time MRI guidance, therapeutic ultrasound ablation, and closed-loop temperature feedback control for precise, incision-free tissue ablation.

Opportunities

The CAPTAIN trial data provides a powerful catalyst to disrupt the prostate cancer treatment standard.
Large, underpenetrated markets in BPH and uterine fibroids offer significant expansion potential.
The integrated MRI-guidance platform is a durable competitive advantage.

Risk Factors

Commercial adoption faces hurdles from entrenched surgical standards and lengthy hospital sales cycles.
Securing and maintaining adequate reimbursement is critical.
The company is not yet profitable and faces competition from lower-cost, less advanced alternatives.

Competitive Landscape

Competes in prostate therapy against robotic surgery, HIFU, cryotherapy, and IRE, with differentiation from real-time MRI guidance and closed-loop control. In BPH, competes with TURP, HoLEP, and minimally invasive devices. In fibroids, competes with other MR-HIFU systems.

More companies in Digital Health & Biotech SaaS →More companies in Canada →